Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.18)
# 1,176
Out of 4,984 analysts
497
Total ratings
43.39%
Success rate
2.42%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $60.57 | +32.08% | 34 | Sep 17, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $27.76 | +65.71% | 25 | Sep 9, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $31 → $34 | $26.48 | +28.40% | 2 | Sep 8, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $15.57 | +124.79% | 23 | Sep 4, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $14 | $7.76 | +80.41% | 18 | Sep 3, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $1 | $1.07 | -6.10% | 17 | Aug 29, 2025 | |
| EVO Evotec SE | Maintains: Buy | $8 → $7 | $3.67 | +90.67% | 10 | Aug 14, 2025 | |
| BHVN Biohaven | Maintains: Buy | $54 → $30 | $14.75 | +103.39% | 15 | Aug 12, 2025 | |
| EOLS Evolus | Maintains: Buy | $27 → $20 | $6.58 | +203.95% | 28 | Aug 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $105 → $115 | $44.34 | +159.36% | 25 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $720 → $774 | $741.53 | +4.38% | 40 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $62.26 | +89.54% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $34.39 | +135.53% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $15.73 | +14.43% | 20 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.01 | +1,143.78% | 26 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $36.93 | +43.51% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.42 | +394.70% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $18.72 | +81.62% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $17.61 | +7.89% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.08 | +476.92% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.64 | +219.43% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.58 | +1,042.86% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $23.61 | +141.42% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $13.96 | +7.49% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.15 | +133.10% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.78 | +46,202.25% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.08 | +825.93% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $175.26 | +3.85% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.19 | +160.78% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $39.47 | -54.40% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $18.68 | -57.16% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $26.46 | +96.52% | 2 | Jun 11, 2019 |
Protagonist Therapeutics
Sep 17, 2025
Reiterates: Buy
Price Target: $80
Current: $60.57
Upside: +32.08%
Alkermes
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $27.76
Upside: +65.71%
Rapport Therapeutics
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $26.48
Upside: +28.40%
Immunovant
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $15.57
Upside: +124.79%
Rezolute
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $7.76
Upside: +80.41%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: $1
Current: $1.07
Upside: -6.10%
Evotec SE
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.67
Upside: +90.67%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $14.75
Upside: +103.39%
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.58
Upside: +203.95%
Praxis Precision Medicines
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $44.34
Upside: +159.36%
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $741.53
Upside: +4.38%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $62.26
Upside: +89.54%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $34.39
Upside: +135.53%
Jun 18, 2025
Reiterates: Buy
Price Target: $18
Current: $15.73
Upside: +14.43%
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $2.01
Upside: +1,143.78%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $36.93
Upside: +43.51%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.42
Upside: +394.70%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $18.72
Upside: +81.62%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $17.61
Upside: +7.89%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.08
Upside: +476.92%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $5.64
Upside: +219.43%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.58
Upside: +1,042.86%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $23.61
Upside: +141.42%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $13.96
Upside: +7.49%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $2.15
Upside: +133.10%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.78
Upside: +46,202.25%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.08
Upside: +825.93%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $175.26
Upside: +3.85%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.19
Upside: +160.78%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $39.47
Upside: -54.40%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $18.68
Upside: -57.16%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $26.46
Upside: +96.52%